| Similar Articles |
 |
Pharmaceutical Executive May 1, 2007 Sarah Houlton |
Global Report: Pure and Simple The european union is set to overhaul the way it monitors drug safety to help make sense of a decentralized system that has been criticized for being ineffective. Will the EC's upcoming drug-safety plan be just what the doctor ordered or end up an indecent proposal?  |
Pharmaceutical Executive June 1, 2011 |
A Lack of Information Why has the EU still not managed to update its rules on information about medicines?  |
Pharmaceutical Executive July 1, 2005 Sarah Houlton |
Global Report: Still Waiting Pharma industry and traders both want a decision on parallel trade in Europe--but not the same one.  |
Pharmaceutical Executive September 1, 2005 Sarah Houlton |
Global Report: Kids 'R' EU After years of delay, the European Parliament is ready to vote on pediatric-testing legislation.  |
Pharmaceutical Executive November 1, 2011 |
Europe Tackles 'Advertising in Disguise' Fears The EC's latest proposals have thrown water on Europe's fiery Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?  |
Pharmaceutical Executive November 1, 2006 Sarah Houlton |
Global Report: 'Bout Time The European Union has been late to enter the fight against counterfeiting. Fed up, Parliament has passed a proposal designed to give its countries the nudge they need.  |
Pharmaceutical Executive November 1, 2013 Timothy Denman |
Supply Chain: Scanning the Future The US and Europe are moving toward the enactment of new legislation that will change the way pharma products are handled and shipped throughout the supply chain.  |
Chemistry World April 24, 2014 Emma Stoye |
European parliament backs new rules on legal highs New regulations that will make it easier to ban legal highs have been backed by the European parliament.  |
Chemistry World August 17, 2015 Anthony King |
Greek crisis puts pressure on pharmaceuticals Supplies of critical drugs to Greek pharmacies have become sparse and erratic as the economic crisis squeezes public spending  |
Pharmaceutical Executive April 1, 2014 |
Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.  |
Pharmaceutical Executive July 1, 2014 |
Europe Gears Up to Attack Counterfeit Medicines -- But Only Some of Them Cross-sector partnership seeks support for a pan-European system to keep fake drugs out, but obstacles are many.  |
Pharmaceutical Executive April 1, 2011 |
Dalli's Formula Fails the Efficacy Test EU leadership on pharma policy leaves many wondering of the right man is at the helm.  |
Chemistry World July 10, 2012 |
Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place.  |
Chemistry World September 30, 2014 |
Transparency measures forced on pharma Previous misdemeanors are compelling the pharmaceutical industry to be more open with financial information and clinical data.  |
Pharmaceutical Executive April 10, 2014 |
Obama Policies Reshape Pharma Marketing Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.  |
Chemistry World November 3, 2015 Ned Stafford |
GM food and feed law falters in EU parliament Both GMO supporters and opponents applauded parliament's rejection of the proposed law.  |
Pharmaceutical Executive May 1, 2011 |
Seeing Through the Transparency Directive The EU is largely powerless when it comes to policies over pharma pricing and reimbursement.  |
Pharmaceutical Executive April 1, 2011 |
Revisiting Reform Courts, Congress review policies and programs shaping drug costs and access.  |
Chemistry World November 18, 2010 Ned Stafford |
New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system.  |
Pharmaceutical Executive January 1, 2011 Jill Wechsler |
Politics & PDUFA Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead.  |
Pharmaceutical Executive October 1, 2011 |
Sweden: Setting the Pace for Global Pharma On health system decentralization, regulatory convergence, drug detailing, promotion, patient information, the environment, value-based pricing, and the pursuit of cost-effectiveness, the Nordics have been true innovators over the past decades.  |
Pharmaceutical Executive October 1, 2006 Sarah Houlton |
Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China.  |
Pharmaceutical Executive October 1, 2012 Peter O'Donnell |
Richard Bergstrom -- Europe's Medicine Man The new head of the European Federation of Pharmaceutical Industries and Associations faces a Promethean challenge: selling the merits of costly science and innovation in an era of bristling competition, fiscal crisis, and declining demographics.  |
Pharmaceutical Executive December 1, 2008 Jill Wechsler |
Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers.  |
Pharmaceutical Executive January 1, 2007 Sarah Houlton |
Global Report: No Satisfaction Germans on both sides of the political spectrum agree that their country's healthcare system needs reform. The latest attempt at change, though, doesn't really meet either side's needs.  |
Chemistry World April 27, 2015 Ned Stafford |
European parliament refuses to back diversion of research cash Key European parliament committees have overwhelmingly rejected a proposal to divert euro 2.7 billion of research funding to help finance a new EU-wide economic stimulus package.  |
Pharmaceutical Executive January 1, 2012 Jill Wechsler |
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.  |
Pharmaceutical Executive January 21, 2014 Comer & Upton |
Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.  |
Pharmaceutical Executive May 1, 2007 Peter Pitts |
Opinion: Are Price Controls the New Black? A revamped version of an old bill calling for drug importation is on the congressional runway. With bipartisan backing and red-hot Rahmed-up rhetoric, the legislation might just pass -- and spell failure for the future of innovative drug development.  |
Pharmaceutical Executive January 1, 2006 Sarah Houlton |
Global Report: The UK's New Code of Conduct Pharma companies' relationships with doctors are being tightened in the United Kingdom, after a major overhaul of the Association of the British Pharmaceutical Industry's Code of Practice.  |
The Motley Fool February 8, 2011 Brian Orelli |
A Few Extra Years of Sales? Yes, Please! An EU-Canadian proposal could help drugmakers.  |
Pharmaceutical Executive January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.  |
Pharmaceutical Executive October 1, 2014 |
Eruptions on the Drug-Pricing Horizon in Europe An escalating political debate over pharma pricing and reimbursement nears the boiling point.  |
Pharmaceutical Executive March 1, 2012 Jill Wechsler |
When Talk is Not So Cheap FDA and industry are pushing user fees, while they struggle with curbs on communications.  |
Pharmaceutical Executive December 1, 2010 |
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs.  |
Pharmaceutical Executive June 1, 2014 |
Hopes High as EU Heads Into Leadership Change The principal drug industry associations in Europe launched a call in mid-May for "an integrated European industrial policy for the pharmaceuticals sector."  |
Pharmaceutical Executive May 1, 2011 Julian Upton |
UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance.  |
Pharmaceutical Executive January 1, 2007 Glass & Poli |
Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges.  |
The Motley Fool July 30, 2010 Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.  |
The Motley Fool January 7, 2005 Brian Gorman |
Canadian Drug Sales Might End Drug makers may not have to worry about cheap pills flooding into the U.S. from across the border, at least for now, offering a small consolation to investors.  |
Chemistry World February 18, 2014 Ned Stafford |
GM maize poised for approval in Europe The European commission is on the verge of authorizing a genetically modified maize for cultivation after ministers from EU member nations last week failed to muster a large enough majority to reject the crop.  |
Pharmaceutical Executive September 1, 2014 |
Peril, Not Progress on Transatlantic Trade Deal Pharma hopes for a deal are fading as the once-hot TTIP talks seem to be on the fizzle in Europe.  |
Chemistry World June 19, 2014 Ned Stafford |
EU plan to let member states decide on GM The European council of environment ministers would allow member states to go it alone and ban the cultivation of genetically modified crops.  |
Pharmaceutical Executive February 1, 2011 Jon Zifferblat |
China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country  |
Chemistry World July 25, 2012 |
Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.  |
Pharmaceutical Executive December 1, 2012 Jill Wechsler |
Obamacare, Innovation and Pricing Tax and budget decisions will shape the healthcare market and drug research and regulation.  |
Pharmaceutical Executive February 1, 2014 |
Will Europe's Regulatory Watchdog Come Of Age In 2014? The author looks at the growing pains of the European Medicine Agency as it faces key policy challenges of 2014.  |
Pharmaceutical Executive November 1, 2013 Jill Wechsler |
Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.  |
The Motley Fool January 28, 2005 Karl Thiel |
Will the FDA Kill Biotech? Proposed legislation could spell changes across the pharmaceutical world. Investors are right to be nervous.  |
Chemistry World January 6, 2014 Sarah Houlton |
Weathering the storm Pharma is in the middle of a strategic crisis, if a report published at the start of 2013 by Roland Berger Strategy Consultants is to be believed.  |